Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

How are circRNAs translated by non-canonical initiation mechanisms?

Diallo LH, Tatin F, David F, Godet AC, Zamora A, Prats AC, Garmy-Susini B, Lacazette E.

Biochimie. 2019 Sep;164:45-52. doi: 10.1016/j.biochi.2019.06.015. Epub 2019 Jun 29. Review.

PMID:
31265859
2.

IRES Trans-Acting Factors, Key Actors of the Stress Response.

Godet AC, David F, Hantelys F, Tatin F, Lacazette E, Garmy-Susini B, Prats AC.

Int J Mol Sci. 2019 Feb 20;20(4). pii: E924. doi: 10.3390/ijms20040924. Review.

3.

Periprostatic Adipose Tissue Favors Prostate Cancer Cell Invasion in an Obesity-Dependent Manner: Role of Oxidative Stress.

Laurent V, Toulet A, Attané C, Milhas D, Dauvillier S, Zaidi F, Clement E, Cinato M, Le Gonidec S, Guérard A, Lehuédé C, Garandeau D, Nieto L, Renaud-Gabardos E, Prats AC, Valet P, Malavaud B, Muller C.

Mol Cancer Res. 2019 Mar;17(3):821-835. doi: 10.1158/1541-7786.MCR-18-0748. Epub 2019 Jan 3.

PMID:
30606769
4.

Lymphatic Vasculature Requires Estrogen Receptor-α Signaling to Protect From Lymphedema.

Morfoisse F, Tatin F, Chaput B, Therville N, Vaysse C, Métivier R, Malloizel-Delaunay J, Pujol F, Godet AC, De Toni F, Boudou F, Grenier K, Dubuc D, Lacazette E, Prats AC, Guillermet-Guibert J, Lenfant F, Garmy-Susini B.

Arterioscler Thromb Vasc Biol. 2018 Jun;38(6):1346-1357. doi: 10.1161/ATVBAHA.118.310997. Epub 2018 Apr 12.

5.

Activated human primary NK cells efficiently kill colorectal cancer cells in 3D spheroid cultures irrespectively of the level of PD-L1 expression.

Lanuza PM, Vigueras A, Olivan S, Prats AC, Costas S, Llamazares G, Sanchez-Martinez D, Ayuso JM, Fernandez L, Ochoa I, Pardo J.

Oncoimmunology. 2018 Feb 12;7(4):e1395123. doi: 10.1080/2162402X.2017.1395123. eCollection 2018.

6.

Therapeutic Benefit and Gene Network Regulation by Combined Gene Transfer of Apelin, FGF2, and SERCA2a into Ischemic Heart.

Renaud-Gabardos E, Tatin F, Hantelys F, Lebas B, Calise D, Kunduzova O, Masri B, Pujol F, Sicard P, Valet P, Roncalli J, Chaufour X, Garmy-Susini B, Parini A, Prats AC.

Mol Ther. 2018 Mar 7;26(3):902-916. doi: 10.1016/j.ymthe.2017.11.007. Epub 2017 Nov 16.

7.

Local production of tenascin-C acts as a trigger for monocyte/macrophage recruitment that provokes cardiac dysfunction.

Abbadi D, Laroumanie F, Bizou M, Pozzo J, Daviaud D, Delage C, Calise D, Gaits-Iacovoni F, Dutaur M, Tortosa F, Renaud-Gabardos E, Douin-Echinard V, Prats AC, Roncalli J, Parini A, Pizzinat N.

Cardiovasc Res. 2018 Jan 1;114(1):123-137. doi: 10.1093/cvr/cvx221.

PMID:
29136112
8.

Dachsous1-Fat4 Signaling Controls Endothelial Cell Polarization During Lymphatic Valve Morphogenesis-Brief Report.

Pujol F, Hodgson T, Martinez-Corral I, Prats AC, Devenport D, Takeichi M, Genot E, Mäkinen T, Francis-West P, Garmy-Susini B, Tatin F.

Arterioscler Thromb Vasc Biol. 2017 Sep;37(9):1732-1735. doi: 10.1161/ATVBAHA.117.309818. Epub 2017 Jul 13.

PMID:
28705793
9.

Apelin modulates pathological remodeling of lymphatic endothelium after myocardial infarction.

Tatin F, Renaud-Gabardos E, Godet AC, Hantelys F, Pujol F, Morfoisse F, Calise D, Viars F, Valet P, Masri B, Prats AC, Garmy-Susini B.

JCI Insight. 2017 Jun 15;2(12). pii: 93887. doi: 10.1172/jci.insight.93887. eCollection 2017 Jun 15.

10.

Therapeutic Benefits and Adverse Effects of Combined Proangiogenic Gene Therapy in Mouse Critical Leg Ischemia.

Lebas B, Galley J, Renaud-Gabardos E, Pujol F, Lenfant F, Garmy-Susini B, Chaufour X, Prats AC.

Ann Vasc Surg. 2017 Apr;40:252-261. doi: 10.1016/j.avsg.2016.08.027. Epub 2016 Nov 27.

11.

Role of hypoxia and vascular endothelial growth factors in lymphangiogenesis.

Morfoisse F, Renaud E, Hantelys F, Prats AC, Garmy-Susini B.

Mol Cell Oncol. 2015 May 27;2(4):e1024821. doi: 10.1080/23723556.2015.1024821. eCollection 2015 Oct-Dec. Review.

12.

Nucleolin Promotes Heat Shock-Associated Translation of VEGF-D to Promote Tumor Lymphangiogenesis.

Morfoisse F, Tatin F, Hantelys F, Adoue A, Helfer AC, Cassant-Sourdy S, Pujol F, Gomez-Brouchet A, Ligat L, Lopez F, Pyronnet S, Courty J, Guillermet-Guibert J, Marzi S, Schneider RJ, Prats AC, Garmy-Susini BH.

Cancer Res. 2016 Aug 1;76(15):4394-405. doi: 10.1158/0008-5472.CAN-15-3140. Epub 2016 Jun 8.

13.

Promoter-Dependent Translation Controlled by p54nrb and hnRNPM during Myoblast Differentiation.

Ainaoui N, Hantelys F, Renaud-Gabardos E, Bunel M, Lopez F, Pujol F, Planes R, Bahraoui E, Pichereaux C, Burlet-Schiltz O, Parini A, Garmy-Susini B, Prats AC.

PLoS One. 2015 Sep 2;10(9):e0136466. doi: 10.1371/journal.pone.0136466. eCollection 2015.

14.

Internal ribosome entry site-based vectors for combined gene therapy.

Renaud-Gabardos E, Hantelys F, Morfoisse F, Chaufour X, Garmy-Susini B, Prats AC.

World J Exp Med. 2015 Feb 20;5(1):11-20. doi: 10.5493/wjem.v5.i1.11. eCollection 2015 Feb 20. Review.

15.

[Lymphangiogenic gene expression adaptation in tumor hypoxic environment].

Morfoisse F, Renaud E, Hantelys F, Prats AC, Garmy-Susini B.

Med Sci (Paris). 2014 May;30(5):506-8. doi: 10.1051/medsci/20143005010. Epub 2014 Jun 13. French. No abstract available.

16.

Hypoxia induces VEGF-C expression in metastatic tumor cells via a HIF-1α-independent translation-mediated mechanism.

Morfoisse F, Kuchnio A, Frainay C, Gomez-Brouchet A, Delisle MB, Marzi S, Helfer AC, Hantelys F, Pujol F, Guillermet-Guibert J, Bousquet C, Dewerchin M, Pyronnet S, Prats AC, Carmeliet P, Garmy-Susini B.

Cell Rep. 2014 Jan 16;6(1):155-67. doi: 10.1016/j.celrep.2013.12.011. Epub 2014 Jan 2.

17.

Role of hypoxia and vascular endothelial growth factors in lymphangiogenesis.

Morfoisse F, Renaud E, Hantelys F, Prats AC, Garmy-Susini B.

Mol Cell Oncol. 2014 Aug 13;1(1):e29907. doi: 10.4161/mco.29907. eCollection 2014. Review.

18.

p53 acts as a safeguard of translational control by regulating fibrillarin and rRNA methylation in cancer.

Marcel V, Ghayad SE, Belin S, Therizols G, Morel AP, Solano-Gonzàlez E, Vendrell JA, Hacot S, Mertani HC, Albaret MA, Bourdon JC, Jordan L, Thompson A, Tafer Y, Cong R, Bouvet P, Saurin JC, Catez F, Prats AC, Puisieux A, Diaz JJ.

Cancer Cell. 2013 Sep 9;24(3):318-30. doi: 10.1016/j.ccr.2013.08.013.

19.

Hypothalamic apelin/reactive oxygen species signaling controls hepatic glucose metabolism in the onset of diabetes.

Drougard A, Duparc T, Brenachot X, Carneiro L, Gouazé A, Fournel A, Geurts L, Cadoudal T, Prats AC, Pénicaud L, Vieau D, Lesage J, Leloup C, Benani A, Cani PD, Valet P, Knauf C.

Antioxid Redox Signal. 2014 Feb 1;20(4):557-73. doi: 10.1089/ars.2013.5182. Epub 2013 Sep 18.

20.

CXCL4L1-fibstatin cooperation inhibits tumor angiogenesis, lymphangiogenesis and metastasis.

Prats AC, Van den Berghe L, Rayssac A, Ainaoui N, Morfoisse F, Pujol F, Legonidec S, Bikfalvi A, Prats H, Pyronnet S, Garmy-Susini B.

Microvasc Res. 2013 Sep;89:25-33. doi: 10.1016/j.mvr.2013.05.005. Epub 2013 Jun 4.

21.

The p53 isoform, Δ133p53α, stimulates angiogenesis and tumour progression.

Bernard H, Garmy-Susini B, Ainaoui N, Van Den Berghe L, Peurichard A, Javerzat S, Bikfalvi A, Lane DP, Bourdon JC, Prats AC.

Oncogene. 2013 Apr 25;32(17):2150-60. doi: 10.1038/onc.2012.242. Epub 2012 Jun 25.

22.

p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients.

Bourdon JC, Khoury MP, Diot A, Baker L, Fernandes K, Aoubala M, Quinlan P, Purdie CA, Jordan LB, Prats AC, Lane DP, Thompson AM.

Breast Cancer Res. 2011 Jan 20;13(1):R7. doi: 10.1186/bcr2811.

23.

p53 directly transactivates Δ133p53α, regulating cell fate outcome in response to DNA damage.

Aoubala M, Murray-Zmijewski F, Khoury MP, Fernandes K, Perrier S, Bernard H, Prats AC, Lane DP, Bourdon JC.

Cell Death Differ. 2011 Feb;18(2):248-58. doi: 10.1038/cdd.2010.91. Epub 2010 Aug 6.

24.

Dysregulation of ribosome biogenesis and translational capacity is associated with tumor progression of human breast cancer cells.

Belin S, Beghin A, Solano-Gonzàlez E, Bezin L, Brunet-Manquat S, Textoris J, Prats AC, Mertani HC, Dumontet C, Diaz JJ.

PLoS One. 2009 Sep 25;4(9):e7147. doi: 10.1371/journal.pone.0007147.

25.

IRES-based vector coexpressing FGF2 and Cyr61 provides synergistic and safe therapeutics of lower limb ischemia.

Rayssac A, Neveu C, Pucelle M, Van den Berghe L, Prado-Lourenco L, Arnal JF, Chaufour X, Prats AC.

Mol Ther. 2009 Dec;17(12):2010-9. doi: 10.1038/mt.2009.211. Epub 2009 Sep 8.

26.

Fibroblast growth factor 1 induced during myogenesis by a transcription-translation coupling mechanism.

Conte C, Ainaoui N, Delluc-Clavières A, Khoury MP, Azar R, Pujol F, Martineau Y, Pyronnet S, Prats AC.

Nucleic Acids Res. 2009 Sep;37(16):5267-78. doi: 10.1093/nar/gkp550. Epub 2009 Jun 26.

27.

FGF2 translationally induced by hypoxia is involved in negative and positive feedback loops with HIF-1alpha.

Conte C, Riant E, Toutain C, Pujol F, Arnal JF, Lenfant F, Prats AC.

PLoS One. 2008 Aug 27;3(8):e3078. doi: 10.1371/journal.pone.0003078.

28.

Potent activation of FGF-2 IRES-dependent mechanism of translation during brain development.

Audigier S, Guiramand J, Prado-Lourenco L, Conte C, Gonzalez-Herrera IG, Cohen-Solal C, Récasens M, Prats AC.

RNA. 2008 Sep;14(9):1852-64. doi: 10.1261/rna.790608. Epub 2008 Aug 1.

29.

Efficient gene transfer in skeletal muscle with AAV-derived bicistronic vector using the FGF-1 IRES.

Delluc-Clavières A, Le Bec C, Van den Berghe L, Conte C, Allo V, Danos O, Prats AC.

Gene Ther. 2008 Aug;15(15):1090-8. doi: 10.1038/gt.2008.49. Epub 2008 Mar 27.

PMID:
18369321
30.

Long term expression of bicistronic vector driven by the FGF-1 IRES in mouse muscle.

Allera-Moreau C, Delluc-Clavières A, Castano C, Van den Berghe L, Golzio M, Moreau M, Teissié J, Arnal JF, Prats AC.

BMC Biotechnol. 2007 Oct 28;7:74.

31.

Low dietary inorganic phosphate affects the brain by controlling apoptosis, cell cycle and protein translation.

Jin H, Hwang SK, Kwon JT, Lee YS, An GH, Lee KH, Prats AC, Morello D, Beck GR Jr, Cho MH.

J Nutr Biochem. 2008 Jan;19(1):16-25. Epub 2007 May 16.

PMID:
17509857
32.

Translational induction of VEGF internal ribosome entry site elements during the early response to ischemic stress.

Bornes S, Prado-Lourenco L, Bastide A, Zanibellato C, Iacovoni JS, Lacazette E, Prats AC, Touriol C, Prats H.

Circ Res. 2007 Feb 16;100(3):305-8. Epub 2007 Jan 25.

PMID:
17255526
33.

The use of IRES-based bicistronic vectors allows the stable expression of recombinant G-protein coupled receptors such as NPY5 and histamine 4.

Allera-Moreau C, Chomarat P, Audinot V, Cogé F, Gillard M, Martineau Y, Boutin JA, Prats AC.

Biochimie. 2006 Jun;88(6):737-46. Epub 2006 Jun 21.

34.

Testosterone regulates FGF-2 expression during testis maturation by an IRES-dependent translational mechanism.

Gonzalez-Herrera IG, Prado-Lourenco L, Pileur F, Conte C, Morin A, Cabon F, Prats H, Vagner S, Bayard F, Audigier S, Prats AC.

FASEB J. 2006 Mar;20(3):476-8. Epub 2006 Jan 19. Erratum in: FASEB J. 2006 Jul;20(9):1573-4.

PMID:
16423876
35.

A high inorganic phosphate diet perturbs brain growth, alters Akt-ERK signaling, and results in changes in cap-dependent translation.

Jin H, Hwang SK, Yu K, Anderson HK, Lee YS, Lee KH, Prats AC, Morello D, Beck GR Jr, Cho MH.

Toxicol Sci. 2006 Mar;90(1):221-9. Epub 2005 Dec 7.

PMID:
16338957
36.

IRES-dependent regulation of FGF-2 mRNA translation in pathophysiological conditions in the mouse.

Gonzalez-Herrera IG, Prado-Lourenco L, Teshima-Kondo S, Kondo K, Cabon F, Arnal JF, Bayard F, Prats AC.

Biochem Soc Trans. 2006 Feb;34(Pt 1):17-21. Review.

PMID:
16246170
37.
38.

Antiangiogenic properties of fibstatin, an extracellular FGF-2-binding polypeptide.

Bossard C, Van den Berghe L, Laurell H, Castano C, Cerutti M, Prats AC, Prats H.

Cancer Res. 2004 Oct 15;64(20):7507-12.

39.

Internal ribosome entry site structural motifs conserved among mammalian fibroblast growth factor 1 alternatively spliced mRNAs.

Martineau Y, Le Bec C, Monbrun L, Allo V, Chiu IM, Danos O, Moine H, Prats H, Prats AC.

Mol Cell Biol. 2004 Sep;24(17):7622-35.

40.

Hyperglycemia upregulates translation of the fibroblast growth factor 2 mRNA in mouse aorta via internal ribosome entry site.

Teshima-Kondo S, Kondo K, Prado-Lourenco L, Gonzalez-Herrera IG, Rokutan K, Bayard F, Arnal JF, Prats AC.

FASEB J. 2004 Oct;18(13):1583-5. Epub 2004 Aug 2.

41.

Use and comparison of different internal ribosomal entry sites (IRES) in tricistronic retroviral vectors.

Douin V, Bornes S, Creancier L, Rochaix P, Favre G, Prats AC, Couderc B.

BMC Biotechnol. 2004 Jul 27;4:16.

42.

Role of fibroblast growth factor-2 isoforms in the effect of estradiol on endothelial cell migration and proliferation.

Garmy-Susini B, Delmas E, Gourdy P, Zhou M, Bossard C, Bugler B, Bayard F, Krust A, Prats AC, Doetschman T, Prats H, Arnal JF.

Circ Res. 2004 May 28;94(10):1301-9. Epub 2004 Apr 8.

PMID:
15073041
43.

Estrogens and atherosclerosis.

Arnal JF, Gourdy P, Elhage R, Garmy-Susini B, Delmas E, Brouchet L, Castano C, Barreira Y, Couloumiers JC, Prats H, Prats AC, Bayard F.

Eur J Endocrinol. 2004 Feb;150(2):113-7. Review.

PMID:
14763907
44.

Generation of protein isoform diversity by alternative initiation of translation at non-AUG codons.

Touriol C, Bornes S, Bonnal S, Audigier S, Prats H, Prats AC, Vagner S.

Biol Cell. 2003 May-Jun;95(3-4):169-78. Review.

PMID:
12867081
45.

A single internal ribosome entry site containing a G quartet RNA structure drives fibroblast growth factor 2 gene expression at four alternative translation initiation codons.

Bonnal S, Schaeffer C, Créancier L, Clamens S, Moine H, Prats AC, Vagner S.

J Biol Chem. 2003 Oct 10;278(41):39330-6. Epub 2003 Jul 11.

46.

Unr is required in vivo for efficient initiation of translation from the internal ribosome entry sites of both rhinovirus and poliovirus.

Boussadia O, Niepmann M, Créancier L, Prats AC, Dautry F, Jacquemin-Sablon H.

J Virol. 2003 Mar;77(6):3353-9.

47.

Translational control of gene expression: role of IRESs and consequences for cell transformation and angiogenesis.

Prats AC, Prats H.

Prog Nucleic Acid Res Mol Biol. 2002;72:367-413. Review.

PMID:
12206457
48.

New ways of initiating translation in eukaryotes.

Schneider R, Agol VI, Andino R, Bayard F, Cavener DR, Chappell SA, Chen JJ, Darlix JL, Dasgupta A, Donzé O, Duncan R, Elroy-Stein O, Farabaugh PJ, Filipowicz W, Gale M Jr, Gehrke L, Goldman E, Groner Y, Harford JB, Hatzglou M, He B, Hellen CU, Hentze MW, Hershey J, Hershey P, Hohn T, Holcik M, Hunter CP, Igarashi K, Jackson R, Jagus R, Jefferson LS, Joshi B, Kaempfer R, Katze M, Kaufman RJ, Kiledjian M, Kimball SR, Kimchi A, Kirkegaard K, Koromilas AE, Krug RM, Kruys V, Lamphear BJ, Lemon S, Lloyd RE, Maquat LE, Martinez-Salas E, Mathews MB, Mauro VP, Miyamoto S, Mohr I, Morris DR, Moss EG, Nakashima N, Palmenberg A, Parkin NT, Pe'ery T, Pelletier J, Peltz S, Pestova TV, Pilipenko EV, Prats AC, Racaniello V, Read GS, Rhoads RE, Richter JD, Rivera-Pomar R, Rouault T, Sachs A, Sarnow P, Scheper GC, Schiff L, Schoenberg DR, Semler BL, Siddiqui A, Skern T, Sonenberg N, Sossin W, Standart N, Tahara SM, Thomas AA, Toulmé JJ, Wilusz J, Wimmer E, Witherell G, Wormington M.

Mol Cell Biol. 2001 Dec;21(23):8238-46. No abstract available.

49.

p53 directs conformational change and translation initiation blockade of human fibroblast growth factor 2 mRNA.

Galy B, Créancier L, Prado-Lourenço L, Prats AC, Prats H.

Oncogene. 2001 Aug 2;20(34):4613-20.

50.

Translation of the human c-myc P0 tricistronic mRNA involves two independent internal ribosome entry sites.

Nanbru C, Prats AC, Droogmans L, Defrance P, Huez G, Kruys V.

Oncogene. 2001 Jul 12;20(31):4270-80.

Supplemental Content

Loading ...
Support Center